About Event

Are you ready to join the HFpEF Drug Discovery & Development movement?

Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes.

The HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures.

With 20+ hours of content, an interactive workshop, and over 5 hours of networking with key industry leaders from  Amgen, Cardiobiopharma, AstraZeneca, NeoProgen, Eli Lilly, Bayer, Novartis, and more, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field.

Make this your 2022 must-attend meeting and network with 80+ senior CSOs, CEOs, research scientists, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide.

Unmissable Highlights Include:

Learn the outcomes of EMPEROR-Preserved with Boehringer Ingelheim to set up future trials for success

Investigate the relationship of other comorbidities with HFpEF, with AstraZeneca and Novo Nordisk providing a holistic overview of patient health

Uncover Next-Generation Regulatory Genome Targets for Cardiac Fibrosis and other emerging therapeutics with HAYA Therapeutics to revive your therapeutic approach and treat HFpEF more successfully.

Scrutinize common mistakes biopharma make when exploring new therapeutic targets and learn how to avoid them with Dr Sheldon Litwin to understand how to design & execute a foolproof plan to successfully identify & validate new HFpEF patients.

Analyze current evaluations for quality of life for HFpEF patients and the major impact of fine-tuning this definition alters the drug development industry